In this article published in Frontiers in Molecular Neuroscience in 2020, Raimundo et al. discuss the role of Islet Amyloid Polypeptide (IAPP), AKA amylin, as a potential accomplice to Amyloid-β (Aβ) in the pathology of Alzheimer's disease (AD).
IAPP is a peptide hormone produced by pancreatic beta-cells and is involved in glucose regulation. However, it has also been found to accumulate in the brain, especially in individuals with AD.
The researchers review evidence suggesting that IAPP can interact with Aβ, a hallmark protein associated with AD pathology. They propose that the interaction between IAPP and Aβ might promote the aggregation and accumulation of both peptides in the brain, potentially exacerbating neurodegenerative processes in AD.
The study highlights the potential role of IAPP as a partner in crime with Aβ, contributing to the development and progression of AD pathology. Understanding the relationship between IAPP and Aβ may provide valuable insights into the underlying mechanisms of AD and could be relevant for the development of therapeutic strategies targeting these pathological processes.
Overall, the article sheds light on the complex interplay between different peptides, particularly IAPP and Aβ, in the context of AD pathology. Further research is needed to fully elucidate the molecular mechanisms and clinical implications of their interactions and how they may contribute to the onset and progression of Alzheimer's disease.